| ASBAH, Layka Abbasi, Iria VAZQUEZ, Loredana VECCHIONE, Eva BUDINSKÁ, Veerle DE VRIENDT, Maria Francesca BAIETTI, Mikhail STEKLOV, Bart JACOBS, Nicholas HOE, Sharat SINGH, Naga-Sailaja IMJETI, Pascale ZIMMERMANN, Anna SABLINA and Sabine TEJPAR. The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling. Oncotarget. New York: Impact Journals, 2014, vol. 5, No 20, p. 10070-10083. ISSN 1949-2553. |
Other formats:
BibTeX
LaTeX
RIS
@article{1215467,
author = {Asbah, Layka Abbasi and Vazquez, Iria and Vecchione, Loredana and Budinská, Eva and De Vriendt, Veerle and Baietti, Maria Francesca and Steklov, Mikhail and Jacobs, Bart and Hoe, Nicholas and Singh, Sharat and Imjeti, NagaandSailaja and Zimmermann, Pascale and Sablina, Anna and Tejpar, Sabine},
article_location = {New York},
article_number = {20},
keywords = {EGFR; PTPRO; phosphatase; SRC kinase; EGFR inhibitor; colon cancer},
language = {eng},
issn = {1949-2553},
journal = {Oncotarget},
title = {The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling},
volume = {5},
year = {2014}
}
TY - JOUR
ID - 1215467
AU - Asbah, Layka Abbasi - Vazquez, Iria - Vecchione, Loredana - Budinská, Eva - De Vriendt, Veerle - Baietti, Maria Francesca - Steklov, Mikhail - Jacobs, Bart - Hoe, Nicholas - Singh, Sharat - Imjeti, Naga-Sailaja - Zimmermann, Pascale - Sablina, Anna - Tejpar, Sabine
PY - 2014
TI - The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling
JF - Oncotarget
VL - 5
IS - 20
SP - 10070-10083
EP - 10070-10083
PB - Impact Journals
SN - 19492553
KW - EGFR
KW - PTPRO
KW - phosphatase
KW - SRC kinase
KW - EGFR inhibitor
KW - colon cancer
N2 - Inappropriate activation of epidermal growth factor receptor (EGFR) plays a causal role in many cancers including colon cancer. The activation of EGFR by phosphorylation is balanced by receptor kinase and protein tyrosine phosphatase activities. However, the mechanisms of negative EGFR regulation by tyrosine phosphatases remain largely unexplored. Our previous results indicate that protein tyrosine phosphatase receptor type O (PTPRO) is down-regulated in a subset of colorectal cancer (CRC) patients with a poor prognosis. Here we identified PTPRO as a phosphatase that negatively regulates SRC by directly dephosphorylating Y416 phosphorylation site. SRC activation triggered by PTPRO down-regulation induces phosphorylation of both EGFR at Y845 and the c-CBL ubiquitin ligase at Y731. Increased EGFR phosphorylation at Y845 promotes its receptor activity, whereas enhanced phosphorylation of c-CBL triggers its degradation promoting EGFR stability. Importantly, hyperactivation of SRC/EGFR signaling triggered by loss of PTPRO leads to high resistance of colon cancer to EGFR inhibitors. Our results not only highlight the PTPRO contribution in negative regulation of SRC/EGFR signaling but also suggest that tumors with low PTPRO expression may be therapeutically targetable by anti-SRC therapies.
ER -
ASBAH, Layka Abbasi, Iria VAZQUEZ, Loredana VECCHIONE, Eva BUDINSKÁ, Veerle DE VRIENDT, Maria Francesca BAIETTI, Mikhail STEKLOV, Bart JACOBS, Nicholas HOE, Sharat SINGH, Naga-Sailaja IMJETI, Pascale ZIMMERMANN, Anna SABLINA and Sabine TEJPAR. The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling. \textit{Oncotarget}. New York: Impact Journals, 2014, vol.~5, No~20, p.~10070-10083. ISSN~1949-2553.
|
